Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Name

Click to order products descending

Display 15 Products per page

VB-111
Read More
VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin

(bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data

from the Phase III GLOBE study.
April 13, 2016
Find out more
Vasotec
Read More
Vasotec’s (enalapril; Merck & Co/Valeant) role in chronic heart failure (CHF) is severely limited by

competition from generic equivalents.
August 2, 2016
Find out more
Vascepa
Read More
Vascepa (icosapent ethyl) is marketed by Amarin for the treatment of severe hypertriglyceridemia. The molecule itself is a semi-synthetic, highly purified derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).
November 20, 2019
Find out more
Vargatef
Read More
Boehringer Ingelheim will hope to increase Vargatef’s (nintedanib) market share at second-line despite

rising competition in this setting.
August 30, 2016
Find out more
Valoctocogene Roxaparvovec
Read More
Valoctocogene roxaparvovec (BioMarin), also known as valrox, is an adeno-associated virus-mediated gene therapy that delivers human B domain-deleted coagulation factor VIII (fVIII) to patients with hemophilia A.
May 20, 2018
Find out more
V180
Read More
Merck & Co’s adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes (DEN-1 strain 258848, DEN-2 strain PR159 S1, DEN-3 strain CH53489, and DEN-4 strain H241).
January 4, 2018
Find out more
V114
Read More
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
December 21, 2018
Find out more
Utibron Neohaler
Read More
Novartis, under license from Vectura and Sosei, developed Utibron, a once-daily long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination product containing indacaterol and glycopyrrolate.
July 31, 2018
Find out more
Uptravi
Read More
Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
Upadacitinib
Read More
Upadacitinib (AbbVie) is an oral small molecule inhibitor of Janus kinase (JAK)-1 that is being developed in several indications including Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and ulcerative colitis.
August 2, 2018
Find out more
umbralisib
Read More
Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.
January 30, 2019
Find out more
Ultibro
Read More
Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for

chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU

markets boost its overall clinical and commercial attractiveness.
April 11, 2016
Find out more
Ularitide
Read More
Ularitide’s (Cardiorentis) favorable results in its pivotal Phase III trial could be a key driver of uptake,

especially as Natrecor (nesiritide; Johnson & Johnson), its major marketed competitor, failed to show

added clinical value and benefit on survival.
March 16, 2016
Find out more
Ublituximab
Read More
Ublituximab (TG Therapeutics) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications.
January 31, 2019
Find out more
Tyvaso
Read More
United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil
October 29, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *